Licensing drugs for diabetes

BMJ (Online)

Volumn 341, Issue 7772, 2010, Pages 513-

  Lehman, Richard ^a   Yudkin, John S ^b   Krumholz, Harlan ^c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c YALE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOSYLATED HEMOGLOBIN; INSULIN; METFORMIN; ROFECOXIB; ROSIGLITAZONE; SULFONYLUREA;

BLINDNESS; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CLINICAL TRIAL; DIABETES MELLITUS; DRUG APPROVAL; DRUG EFFECT; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; EDITORIAL; FOOD AND DRUG ADMINISTRATION; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; KIDNEY FAILURE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; RISK REDUCTION; SIDE EFFECT;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DRUG APPROVAL; HUMANS; HYPOGLYCEMIC AGENTS; SAFETY-BASED DRUG WITHDRAWALS; THIAZOLIDINEDIONES;

EID: 77956526215     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.c4805     Document Type: Editorial

References (11)

1. Food and Drug Administration. Briefing information for the July 13-14, 2010 joint meeting of the Endocrinologic and Metabolic Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee. p556. www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs /EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm218491.htm.
2. Rosen CJ. Perspective: revisiting the rosiglitazone story - lessons learnt. N Engl J Med 2010;363:803-6. [CrossRef] [Medline] [Web of Science]
3. Ross JS, Madigan D, Hill KP, Egilman DS, Wang Y, Krumholz HM. Pooled analysis of rofecoxib placebo-controlled clinical trial data: lessons for postmarket pharmaceutical safety surveillance. Arch Intern Med 2009;169:1976-85. [Abstract/FREE Full text]
4. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53. [CrossRef] [Medline] [Web of Science]
5. Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59. [CrossRef] [Medline]
6. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-72. [CrossRef] [Medline]
7. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven P, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2008;360:129-39. [CrossRef] [Medline] [Web of Science]
8. Yudkin JS, Richter B, Gale EAM. Intensified glucose lowering in type 2 diabetes: time for a reappraisal. Diabetologia2010 Aug 5 [Epub ahead of print].
9. Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohen RM, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 2010;376:419-30. [CrossRef] [Medline] [Web of Science]
10. Institute of Medicine of the National Academies. Evaluation of markers and surrogate endpoints in chronic disease. Consensus report, 2010. www.iom.edu/Reports /2010/Evaluation-of-Biomarkers-and-Surrogate-Endpoints-in- Chronic-Disease.aspx.
11. US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research. Guidance for industry. Diabetes mellitus - evaluating cardiovascular risk in antidiabetic therapies to treat type 2 diabetes. DHHS, 2009.